Sugi Predict

Sugi Predict / Targets / SLC9A3

SLC9A3

Sodium/hydrogen exchanger 3 · P48764 · SLC9A3 on Sugi Atlas →

9,193 patent compounds predicted against SLC9A3, 5,872 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2186534 SCHEMBL2186534 1.00 20/20
SCHEMBL2186536 SCHEMBL2186536 1.00 20/20
SCHEMBL2186573 SCHEMBL2186573 1.00 20/20
SCHEMBL2186578 SCHEMBL2186578 1.00 20/20
SCHEMBL2186669 SCHEMBL2186669 1.00 20/20
SCHEMBL2186703 SCHEMBL2186703 1.00 20/20
SCHEMBL2186707 SCHEMBL2186707 1.00 20/20
SCHEMBL2186708 SCHEMBL2186708 1.00 20/20
SCHEMBL2186710 SCHEMBL2186710 1.00 20/20
SCHEMBL2186712 SCHEMBL2186712 1.00 20/20
SCHEMBL2186914 SCHEMBL2186914 1.00 20/20
SCHEMBL2187142 SCHEMBL2187142 1.00 20/20
SCHEMBL2187149 SCHEMBL2187149 1.00 20/20
SCHEMBL2187228 SCHEMBL2187228 1.00 20/20
SCHEMBL2187232 SCHEMBL2187232 1.00 20/20
SCHEMBL2187463 SCHEMBL2187463 1.00 20/20
SCHEMBL2187818 SCHEMBL2187818 1.00 20/20
SCHEMBL2187886 SCHEMBL2187886 1.00 20/20
SCHEMBL2187891 SCHEMBL2187891 1.00 20/20
SCHEMBL2187898 SCHEMBL2187898 1.00 20/20

Clinical trials — most relevant to SLC9A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Salt Loading and Thiazide Intervention Study PHASE4COMPLETED
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study PHASE4RECRUITING
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure PHASE4RECRUITING
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) PHASE4COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis PHASE3COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor PHASE2COMPLETED
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) PHASE2RECRUITING
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis EARLY_PHASE1RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS nanNOT_YET_RECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Sodium Transport: Genetics and Hypertension nanCOMPLETED
Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter nanCOMPLETED
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital nanUNKNOWN
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Genetics in the Progression of Nephropathies nanRECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Blood Pressure Control in Juveniles - Longitudinal Study nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes nanRECRUITING
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease nanCOMPLETED
Adverse Airway Effects From Tobacco and E-Cigarettes nanUNKNOWN
Hereditary Tubulointerstitial Nephritis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC9A3 binder may also engage these)

ProteinNameSimilarity
P26432 — 1.000 P26432 →
Q28362 — 1.000 Q28362 →
G3X939 — 1.000 G3X939 →
P26433 — 1.000 P26433 →
M5A7P9 — 1.000 M5A7P9 →
B2RXE2 — 1.000 B2RXE2 →
SLC9A5 Sodium/hydrogen exchanger 5 0.995 landscape →
Q9Z0X2 — 0.993 Q9Z0X2 →
G5EBK1 — 0.992 G5EBK1 →
Q8K596 — 0.990 Q8K596 →
P48761 — 0.988 P48761 →
Q8T5S1 — 0.988 Q8T5S1 →
Q6AI14 — 0.988 Q6AI14 →
O13726 — 0.987 O13726 →
Q9R1N3 — 0.987 Q9R1N3 →
Q9Y6M7 — 0.987 Q9Y6M7 →
Q6H4R6 — 0.987 Q6H4R6 →
P23562 — 0.986 P23562 →
Q6VVA6 — 0.986 Q6VVA6 →
Q9Z0S8 — 0.986 Q9Z0S8 →
Q99PD7 — 0.986 Q99PD7 →
Q5DTL9 — 0.986 Q5DTL9 →
Q8BTY2 — 0.986 Q8BTY2 →
Q01345 — 0.986 Q01345 →
P32847 — 0.985 P32847 →
P34586 — 0.985 P34586 →
Q80TL1 — 0.984 Q80TL1 →
Q5RCN4 — 0.984 Q5RCN4 →
Q80T41 — 0.984 Q80T41 →
SLC9A1 Sodium/hydrogen exchanger 1 0.984 landscape →